

Jingshan Tong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7966398/publications.pdf>

Version: 2024-02-01

13
papers

788
citations

758635

12
h-index

1125271

13
g-index

14
all docs

14
docs citations

14
times ranked

1144
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | CDK4/6 Inhibition Suppresses p73 Phosphorylation and Activates DR5 to Potentiate Chemotherapy and Immune Checkpoint Blockade. <i>Cancer Research</i> , 2022, 82, 1340-1352. | 0.4 | 11 |
| 2 | Non-steroidal anti-inflammatory drugs induce immunogenic cell death in suppressing colorectal tumorigenesis. <i>Oncogene</i> , 2021, 40, 2035-2050. | 2.6 | 21 |
| 3 | BET protein degradation triggers DR5-mediated immunogenic cell death to suppress colorectal cancer and potentiate immune checkpoint blockade. <i>Oncogene</i> , 2021, 40, 6566-6578. | 2.6 | 14 |
| 4 | Mcl-1 inhibition overcomes intrinsic and acquired Regorafenib resistance in Colorectal Cancer. <i>Theranostics</i> , 2020, 10, 8098-8110. | 4.6 | 45 |
| 5 | BET Inhibitors Potentiate Chemotherapy and Killing of <i>SPOP</i> -Mutant Colon Cancer Cells via Induction of DR5. <i>Cancer Research</i> , 2019, 79, 1191-1203. | 0.4 | 40 |
| 6 | PUMA amplifies necroptosis signaling by activating cytosolic DNA sensors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 3930-3935. | 3.3 | 121 |
| 7 | Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer. <i>Oncogene</i> , 2018, 37, 4599-4610. | 2.6 | 30 |
| 8 | Mcl-1 Phosphorylation without Degradation Mediates Sensitivity to HDAC Inhibitors by Liberating BH3-Only Proteins. <i>Cancer Research</i> , 2018, 78, 4704-4715. | 0.4 | 49 |
| 9 | Mcl-1 Degradation Is Required for Targeted Therapeutics to Eradicate Colon Cancer Cells. <i>Cancer Research</i> , 2017, 77, 2512-2521. | 0.4 | 118 |
| 10 | <i>FBW7</i> -Dependent Mcl-1 Degradation Mediates the Anticancer Effect of Hsp90 Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1979-1988. | 1.9 | 57 |
| 11 | FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation. <i>Oncogene</i> , 2017, 36, 787-796. | 2.6 | 134 |
| 12 | <i>BRAFV600E</i> -dependent Mcl-1 stabilization leads to everolimus resistance in colon cancer cells. <i>Oncotarget</i> , 2016, 7, 47699-47710. | 0.8 | 51 |
| 13 | Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers. <i>Nature Communications</i> , 2015, 6, 8305. | 5.8 | 97 |